Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research on breast cancer described by scientists at University of Otago
February 5th, 2009
"We postulated that methoxy-substituted cyclic compounds could inhibit estrogen receptor (ER) negative breast cancer growth in vitro. Therefore, this study assessed the cytotoxic potential of various methoxy-substituted cyclic compounds [7,8-dimethoxyflavone, 4-methoxyphenylacetic acid, 2-methoxyphenylacetic acid, 4-methoxybenzophenone, 5-methoxy-1-indanone, and coenzyme Q(0) (CoQ(0))] toward ER-negative human breast cancer cells (MDA-MB-231 and SKBr3)," scientists in Dunedin, New Zealand report. "Cytotoxicity was assessed using the sulforhodamine B assay. CoQ(0) demonstrated the strongest cytotoxicity toward MDA-MB-231 and SKBr3 cells with IC50 values of 1.7 mu mol/l...
Source: Women's Health Weekly (2009-02-05)
|
